Literature DB >> 23183433

A time-to-event pharmacodynamic model describing treatment response in patients with pulmonary tuberculosis using days to positivity in automated liquid mycobacterial culture.

Emmanuel Chigutsa1, Kashyap Patel, Paolo Denti, Marianne Visser, Gary Maartens, Carl M J Kirkpatrick, Helen McIlleron, Mats O Karlsson.   

Abstract

Days to positivity in automated liquid mycobacterial culture have been shown to correlate with mycobacterial load and have been proposed as a useful biomarker for treatment responses in tuberculosis. However, there is currently no quantitative method or model to analyze the change in days to positivity with time on treatment. The objectives of this study were to describe the decline in numbers of mycobacteria in sputum collected once weekly for 8 weeks from patients on treatment for tuberculosis using days to positivity in liquid culture. One hundred forty-four patients with smear-positive pulmonary tuberculosis were recruited from a tuberculosis clinic in Cape Town, South Africa. A nonlinear mixed-effects repeated-time-to-event modeling approach was used to analyze the time-to-positivity data. A biexponential model described the decline in the estimated number of bacteria in patients' sputum samples, while a logistic model with a lag time described the growth of the bacteria in liquid culture. At baseline, the estimated number of rapidly killed bacteria is typically 41 times higher than that of those that are killed slowly. The time to kill half of the rapidly killed bacteria was about 1.8 days, while it was 39 days for slowly killed bacteria. Patients with lung cavitation had higher bacterial loads than patients without lung cavitation. The model successfully described the increase in days to positivity as treatment progressed, differentiating between bacteria that are killed rapidly and those that are killed slowly. Our model can be used to analyze similar data from studies testing new drug regimens.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23183433      PMCID: PMC3553722          DOI: 10.1128/AAC.01876-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  35 in total

1.  Mapping the fitness of Mycobacterium tuberculosis strains: a complex picture.

Authors:  D M O'Sullivan; T D McHugh; S H Gillespie
Journal:  J Med Microbiol       Date:  2010-08-19       Impact factor: 2.472

2.  Evaluation of time to detection of Mycobacterium tuberculosis in broth culture as a determinant for end points in treatment trials.

Authors:  Marc Weiner; Thomas J Prihoda; William Burman; John L Johnson; Stefan Goldberg; Nesri Padayatchi; Paula Duran; Melissa Engle; Grace Muzanye; Roy D Mugerwa; A Willem Sturm
Journal:  J Clin Microbiol       Date:  2010-10-06       Impact factor: 5.948

3.  Modeling of the bacterial growth curve.

Authors:  M H Zwietering; I Jongenburger; F M Rombouts; K van 't Riet
Journal:  Appl Environ Microbiol       Date:  1990-06       Impact factor: 4.792

4.  Performance of three estimation methods in repeated time-to-event modeling.

Authors:  Kristin E Karlsson; Elodie L Plan; Mats O Karlsson
Journal:  AAPS J       Date:  2011-01-13       Impact factor: 4.009

5.  Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months.

Authors:  D A Mitchison
Journal:  Am Rev Respir Dis       Date:  1993-04

6.  Clinical evaluation of the Mycobacteria Growth Indicator Tube (MGIT) compared with radiometric (Bactec) and solid media for isolation of Mycobacterium species.

Authors:  W K Chew; R M Lasaitis; F A Schio; G L Gilbert
Journal:  J Med Microbiol       Date:  1998-09       Impact factor: 2.472

7.  Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis.

Authors:  William J Burman; Stefan Goldberg; John L Johnson; Grace Muzanye; Melissa Engle; Ann W Mosher; Shurjeel Choudhri; Charles L Daley; Sonal S Munsiff; Zhen Zhao; Andrew Vernon; Richard E Chaisson
Journal:  Am J Respir Crit Care Med       Date:  2006-05-04       Impact factor: 21.405

8.  Smear microscopy and culture conversion rates among smear positive pulmonary tuberculosis patients by HIV status in Dar es Salaam, Tanzania.

Authors:  Mbazi Senkoro; Sayoki G Mfinanga; Odd Mørkve
Journal:  BMC Infect Dis       Date:  2010-07-16       Impact factor: 3.090

9.  Serial counts of Mycobacterium tuberculosis in sputum as surrogate markers of the sterilising activity of rifampicin and pyrazinamide in treating pulmonary tuberculosis.

Authors:  R Brindle; J Odhiambo; D Mitchison
Journal:  BMC Pulm Med       Date:  2001       Impact factor: 3.317

Review 10.  Deciphering death: a commentary on Gompertz (1825) 'On the nature of the function expressive of the law of human mortality, and on a new mode of determining the value of life contingencies'.

Authors:  Thomas B L Kirkwood
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-04-19       Impact factor: 6.237

View more
  22 in total

Review 1.  Pharmacologic considerations in use and development of antituberculosis drugs.

Authors:  Geraint Davies
Journal:  Cold Spring Harb Perspect Med       Date:  2014-09-18       Impact factor: 6.915

2.  Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis.

Authors:  Emmanuel Chigutsa; Jotam G Pasipanodya; Marianne E Visser; Paul D van Helden; Peter J Smith; Frederick A Sirgel; Tawanda Gumbo; Helen McIlleron
Journal:  Antimicrob Agents Chemother       Date:  2014-10-13       Impact factor: 5.191

3.  Modeling and Simulation of Pretomanid Pharmacodynamics in Pulmonary Tuberculosis Patients.

Authors:  Michael A Lyons
Journal:  Antimicrob Agents Chemother       Date:  2019-09-30       Impact factor: 5.191

Review 4.  Quantitative assessment of the activity of antituberculosis drugs and regimens.

Authors:  Maxwell T Chirehwa; Gustavo E Velásquez; Tawanda Gumbo; Helen McIlleron
Journal:  Expert Rev Anti Infect Ther       Date:  2019-05-30       Impact factor: 5.091

5.  Transformation Morphisms and Time-to-Extinction Analysis That Map Therapy Duration From Preclinical Models to Patients With Tuberculosis: Translating From Apples to Oranges.

Authors:  Gesham Magombedze; Jotam G Pasipanodya; Shashikant Srivastava; Devyani Deshpande; Marianne E Visser; Emmanuel Chigutsa; Helen McIlleron; Tawanda Gumbo
Journal:  Clin Infect Dis       Date:  2018-11-28       Impact factor: 9.079

6.  Model-Based Relationship between the Molecular Bacterial Load Assay and Time to Positivity in Liquid Culture.

Authors:  Robin J Svensson; Wilber Sabiiti; Gibson S Kibiki; Nyanda E Ntinginya; Nilesh Bhatt; Geraint Davies; Stephen H Gillespie; Ulrika S H Simonsson
Journal:  Antimicrob Agents Chemother       Date:  2019-09-23       Impact factor: 5.191

7.  Transcriptional Adaptation of Drug-tolerant Mycobacterium tuberculosis During Treatment of Human Tuberculosis.

Authors:  Nicholas D Walter; Gregory M Dolganov; Benjamin J Garcia; William Worodria; Alfred Andama; Emmanuel Musisi; Irene Ayakaka; Tran T Van; Martin I Voskuil; Bouke C de Jong; Rebecca M Davidson; Tasha E Fingerlin; Katerina Kechris; Claire Palmer; Payam Nahid; Charles L Daley; Mark Geraci; Laurence Huang; Adithya Cattamanchi; Michael Strong; Gary K Schoolnik; John Lucian Davis
Journal:  J Infect Dis       Date:  2015-03-11       Impact factor: 5.226

Review 8.  Mechanisms of Drug-Induced Tolerance in Mycobacterium tuberculosis.

Authors:  Sander N Goossens; Samantha L Sampson; Annelies Van Rie
Journal:  Clin Microbiol Rev       Date:  2020-10-14       Impact factor: 26.132

9.  Assessing whether isoniazid is essential during the first 14 days of tuberculosis therapy: a phase 2a, open-label, randomised controlled trial.

Authors:  Andreas Diacon; Sachiko Miyahara; Rodney Dawson; Xin Sun; Evelyn Hogg; Kathleen Donahue; Michael Urbanowski; Veronique De Jager; Courtney V Fletcher; Richard Hafner; Susan Swindells; William Bishai
Journal:  Lancet Microbe       Date:  2020-06-08

10.  Effects of Increasing Concentrations of Rifampicin on Different Mycobacterium tuberculosis Lineages in a Whole-Blood Bactericidal Activity Assay.

Authors:  Rupangi Verma; Meera Gurumurthy; Benjamin Chaik Meng Yeo; Qingshu Lu; Claire M Naftalin; Nicholas I Paton
Journal:  Antimicrob Agents Chemother       Date:  2021-12-06       Impact factor: 5.938

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.